
Ginkgo Bioworks Investor Relations Material
Latest events

Q1 2025
Ginkgo Bioworks
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ginkgo Bioworks Holdings Inc
Access all reports
Ginkgo Bioworks Holdings, Inc, a biomolecular engineering company, develops biological manufacturing technologies to program cells for molecular manufacturing systems. Ginkgo Bioworks Holdings software engineering platform uses the widely used programming language Python and its library of bioinformatics functions and statistical methods. Ginkgo Bioworks' programs are designed to modify bacterial genes to make organic compounds such as vanillin, scents to produce civetone in bacteria, Beta-carotene and lycopene in yeast cells, gluconic acid in E. coli; and shikimic acid and artemisinic acid in yeast cells. The company sells its products to pharmaceutical companies including AstraZeneca Group and Eli Lilly & Co; chemical companies including Firmenich SA; flavor, aroma, and fragrance companies; craft breweries; and others.
Key slides for Ginkgo Bioworks Holdings Inc


Q1 2025
Ginkgo Bioworks Holdings Inc


Q3 2024
Ginkgo Bioworks Holdings Inc
Latest articles
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
Ticker symbol
DNA
Country
🇺🇸 United States